» Articles » PMID: 37377473

Psychedelic Therapy in the Treatment of Addiction: the Past, Present and Future

Overview
Specialty Psychiatry
Date 2023 Jun 28
PMID 37377473
Authors
Affiliations
Soon will be listed here.
Abstract

Psychedelic therapy has witnessed a resurgence in interest in the last decade from the scientific and medical communities with evidence now building for its safety and efficacy in treating a range of psychiatric disorders including addiction. In this review we will chart the research investigating the role of these interventions in individuals with addiction beginning with an overview of the current socioeconomic impact of addiction, treatment options, and outcomes. We will start by examining historical studies from the first psychedelic research era of the mid-late 1900s, followed by an overview of the available real-world evidence gathered from naturalistic, observational, and survey-based studies. We will then cover modern-day clinical trials of psychedelic therapies in addiction from first-in-human to phase II clinical trials. Finally, we will provide an overview of the different translational human neuropsychopharmacology techniques, including functional magnetic resonance imaging (fMRI) and positron emission tomography (PET), that can be applied to foster a mechanistic understanding of therapeutic mechanisms. A more granular understanding of the treatment effects of psychedelics will facilitate the optimisation of the psychedelic therapy drug development landscape, and ultimately improve patient outcomes.

Citing Articles

The Therapeutic Potential of Psychedelics in Treating Substance Use Disorders: A Review of Clinical Trials.

Hogea L, Tabugan D, Costea I, Albai O, Nussbaum L, Cojocaru A Medicina (Kaunas). 2025; 61(2).

PMID: 40005395 PMC: 11857248. DOI: 10.3390/medicina61020278.


Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies.

Pulido-Saavedra A, Oliva H, Prudente T, Kitaneh R, Nunes E, Fogg C Cell Mol Life Sci. 2025; 82(1):49.

PMID: 39833376 PMC: 11747050. DOI: 10.1007/s00018-024-05519-2.


The potential of non-psychedelic 5-HT2A agents in the treatment of substance use disorders: a narrative review of the clinical literature.

Pulido-Saavedra A, Borelli A, Kitaneh R, Alrafayia M, Jalilian-Khave L, Funaro M Expert Opin Pharmacother. 2024; 26(2):133-146.

PMID: 39708346 PMC: 11786980. DOI: 10.1080/14656566.2024.2446623.


Neuroimaging and the Investigation of Drug-Drug Interactions Involving Psychedelics.

Wall M, Harding R, Ertl N, Barba T, Zafar R, Sweeney M Neurosci Insights. 2024; 19:26331055241286518.

PMID: 39386147 PMC: 11462571. DOI: 10.1177/26331055241286518.


Psychedelics: From Cave Art to 21st-Century Medicine for Addiction.

Vamvakopoulou I, Nutt D Eur Addict Res. 2024; 30(5):302-320.

PMID: 39321788 PMC: 11527458. DOI: 10.1159/000540062.


References
1.
Gattuso J, Perkins D, Ruffell S, Lawrence A, Hoyer D, Jacobson L . Default Mode Network Modulation by Psychedelics: A Systematic Review. Int J Neuropsychopharmacol. 2022; 26(3):155-188. PMC: 10032309. DOI: 10.1093/ijnp/pyac074. View

2.
Taylor E, Murphy A, Boyapati V, Ersche K, Flechais R, Kuchibatla S . Impulsivity in abstinent alcohol and polydrug dependence: a multidimensional approach. Psychopharmacology (Berl). 2016; 233(8):1487-99. PMC: 4819593. DOI: 10.1007/s00213-016-4245-6. View

3.
Connolly C, Foxe J, Nierenberg J, Shpaner M, Garavan H . The neurobiology of cognitive control in successful cocaine abstinence. Drug Alcohol Depend. 2011; 121(1-2):45-53. PMC: 3262906. DOI: 10.1016/j.drugalcdep.2011.08.007. View

4.
Uddin L . Salience processing and insular cortical function and dysfunction. Nat Rev Neurosci. 2014; 16(1):55-61. DOI: 10.1038/nrn3857. View

5.
Noller G, Frampton C, Yazar-Klosinski B . Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2017; 44(1):37-46. DOI: 10.1080/00952990.2017.1310218. View